Compare · BIAF vs SLGC
BIAF vs SLGC
Side-by-side comparison of bioAffinity Technologies Inc. (BIAF) and SomaLogic Inc. (SLGC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIAF and SLGC operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- SLGC is the larger of the two at $1.43B, about 429.4x BIAF ($3.3M).
- BIAF has hit the wire 4 times in the past 4 weeks while SLGC has been quiet.
- SLGC has more recent analyst coverage (6 ratings vs 0 for BIAF).
- Company
- bioAffinity Technologies Inc.
- SomaLogic Inc.
- Price
- $0.70-2.44%
- $2.09-5.43%
- Market cap
- $3.3M
- $1.43B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 2021
- News (4w)
- 4
- 0
- Recent ratings
- 0
- 6
Latest BIAF
- bioAffinity Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues
- bioAffinity Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells
- bioAffinity Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering
- bioAffinity Technologies Announces Closing of $3.2 Million Offering
- SEC Form 424B4 filed by bioAffinity Technologies Inc.
- WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offering
- bioAffinity Technologies Announces Pricing of $3.2 Million Offering
Latest SLGC
- OncoHost Selected to Present in Oral Minisymposium at American Association of Cancer Research (AACR) Annual Meeting 2024
- SEC Form SC 13G/A filed by SomaLogic Inc. (Amendment)
- SEC Form SC 13G/A filed by SomaLogic Inc. (Amendment)
- SEC Form 15-12G filed by SomaLogic Inc.
- SEC Form EFFECT filed by SomaLogic Inc.
- SEC Form EFFECT filed by SomaLogic Inc.
- Taich Adam returned 48,425 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Ryan Jason
- Roelke Alison Marie returned 17,143 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Post Richard A returned 57,430 shares to the company, closing all direct ownership in the company (SEC Form 4)